WO2024180501 - METHOD OF LYOPHILISATION
National phase entry is expected:
Publication Number
WO/2024/180501
Publication Date
06.09.2024
International Application No.
PCT/IB2024/051928
International Filing Date
28.02.2024
Title **
[English]
METHOD OF LYOPHILISATION
[French]
PROCÉDÉ DE LYOPHILISATION
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Rue de l'Institut 89
B-1330 Rixensart, BE
Inventors
MATHOT, Frédéric
rue de l'institut 89
B-1330 Rixensart, BE
LALEMAN, Frederik
c/o rue de l'institut 89
B-1330 Rixensart, BE
BOURLES, Erwan
rue de l'institut 89
B-1330 Rixensart, BE
Priority Data
2303019.0
01.03.2023
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2004 | |
| EPO | Filing, Examination | 9273 | |
| Japan | Filing | 535 | |
| South Korea | Filing | 576 | |
| USA | Filing, Examination | 6685 |
Total: 19073 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides lyophilised pharmaceutical compositions and methods of making said lyophilised pharmaceutical compositions. More particularly, the present invention provides lyophilised pharmaceutical compositions comprising nucleic acid and lipid carrier particles and methods of making said lyophilised pharmaceutical compositions. The provided lyophilised compositions have improved critical quality attributes (CQAs) and the provided methods prevent the need for a deep-freeze cold chain. The present invention further provides the use of said lyophilised pharmaceutical compositions in medicine.[French]
La présente invention concerne des compositions pharmaceutiques lyophilisées et des procédés de fabrication desdites compositions pharmaceutiques lyophilisées. Plus particulièrement, la présente invention concerne des compositions pharmaceutiques lyophilisées comprenant des particules porteuses d'acides nucléiques et de lipides et des procédés de fabrication desdites compositions pharmaceutiques lyophilisées. Les compositions lyophilisées selon l'invention ont des attributs de qualité critiques (AQC) améliorés et les procédés selon l'invention évitent la nécessité d'une chaîne froide de surgélation. La présente invention concerne en outre l'utilisation desdites compositions pharmaceutiques lyophilisées en médecine.